Evidence map›Paper›PMID 26719702›Full record

ArticleOncoTargets and therapy2015

Prognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib.

Tulay Kus, Gokmen Aktas, Alper Sevinc, Mehmet Emin Kalender, Mustafa Yilmaz, Seval Kul, Serdar Oztuzcu, Cemil Oktay, Celaletdin Camci

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2016
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tulay KusDepartment of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Gokmen AktasDepartment of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Alper SevincDepartment of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Mehmet Emin KalenderDepartment of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Mustafa YilmazDepartment of Nuclear Medicine, University of Gaziantep, Gaziantep, Turkey.
Seval KulDepartment of Biostatistics, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey.
Serdar OztuzcuDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey.
Cemil OktayDepartment of Radiology, Faculty of Medicine, University of Akdeniz, Antalya, Turkey.
Celaletdin CamciDepartment of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Gaziantep University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate whether the initial maximum standardized uptake value (SUVmax) on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) has a prognostic significance in metastatic lung adenocarcinoma. PATIENTS AND

methodsSixty patients (24 females, mean age: 57.9±12 years) with metastatic stage lung adenocarcinoma who used erlotinib and underwent (18)F-FDG PET/CT at the time of diagnosis between May 2010 and May 2014 were enrolled in this retrospective study. The patients were stratified according to the median SUVmax value, which was found as 11. Progression-free survival (PFS) rates for 3, 6, and 12 months were examined for SUVmax values and epidermal growth factor receptor (EGFR) mutation status.

resultsThe number of EGFR-sensitizing mutation positive/negative/unknown was 26/17/17, respectively, and the number of patients using erlotinib at first-line, second-line, and third-line therapy was 15, 31, and 14 consecutively. The PFS rates of EGFR mutation positive, negative, and unknown patients for 3 months were 73.1%, 35.3%, and 41.2% (P=0.026, odds ratio [OR]=4.39; 95% confidence interval [CI]: 1.45-13.26), respectively. The PFS rates of EGFR positive, negative, and unknown patients for 6 months were 50%, 29.4%, and 29.4% (P=0.267, OR: 2.4; 95% CI: 0.82-6.96), respectively. The PFS rates of EGFR positive, negative, and unknown patients for 12 months were 42.3%, 29.4%, 23.5% (P=0.408, OR: 2.0; 95% CI: 0.42-5.26), respectively. Thirty-one of 60 patients had SUVmax values ≤11. The PFS rates for 3, 6, and 12 months were 70.5%/28% (P=0.001, OR=9.0; 95% CI: 2.79-29.04), 61.7%/8% (P<0.001, OR=28.35; 95% CI: 5.5-143), and 52.9%/8% (P<0.001, OR=18.69; 95% CI: 3.76-92.9) for low SUVmax (≤11) group/high SUVmax (>11) group, respectively.

conclusionInitial SUVmax value on (18)F-FDG PET/CT is found to be a prognostic factor anticipating the response to erlotinib for 3, 6, and 12-month rates of PFS in both EGFR-sensitizing mutation and wild-type tumor group.

Indexed as

18F-fluorodeoxyglucose positron emission tomography/computed tomographyerlotiniblung adenocarcinomamaximum standardized uptake valueprognosistreatment response

Identifiers

PMID26719702
PMCPMC4689261
OpenAlexW2209212229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.